Aytu Biopharma (AYTU) Current Deferred Revenue (2014 - 2020)

Aytu Biopharma (AYTU) has 6 years of Current Deferred Revenue data on file, last reported at $475680.0 in Q4 2020.

• Current Deferred Revenue for Q4 2020 came in at $475680.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $475680.0 (changed N/A YoY), and the FY2020 annual result was $339336.0, changed N/A from the prior year.
• Current Deferred Revenue rose to $475680.0 in Q4 2020 per AYTU's latest filing, from $232576.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $475680.0 in Q4 2020 and troughed at $1450.0 in Q2 2018.
• A 4-year average of $116978.0 and a median of $10331.5 in 2017 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 192.25% in 2018 and fell as far as 78.27% in 2018.
• A 4-year view of Current Deferred Revenue shows it stood at $85714.0 in 2016, then slumped by 94.42% to $4787.0 in 2017, then soared by 192.25% to $13990.0 in 2018, then surged by 3300.14% to $475680.0 in 2020.
• Business Quant data shows AYTU's Current Deferred Revenue at $475680.0 in Q4 2020, $232576.0 in Q3 2020, and $339336.0 in Q2 2020.